Investing

Autolus Therapeutics : AUTL

AUTL

Stock Data

$1.47

$0.06 (4.26%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Autolus Therapeutics plc is a London-based biopharmaceutical company focused on pioneering T cell therapies for cancer treatment. It's known for its innovative approach in developing therapies that target specific types of cancer cells, with its leading program, obecabtagene autoleucel, showing promise in adult and pediatric acute lymphoblastic leukemia (ALL). Additionally, Autolus is exploring treatments for peripheral T-cell lymphoma and neuroblastoma, among others, through its diverse pipeline of investigational therapies. Founded in 2014, the company is at the forefront of utilizing T cell engineering to combat cancer.

All Autolus Therapeutics Articles

2 Articles

Trey Thoelcke | Aug 6, 2024 at 9:15 AM EDT

Prediction: This Pharma Stock Will Be the Best Performer the Rest of 2024

Market pullbacks can make nervous investors leery of investing in industries that are more speculative. Wall Street still has big…

Chris Lange | Jun 14, 2021 at 9:17 AM EDT

Monday’s Analyst Upgrades and Downgrades: Chipotle, CRISPR, Hess Midstream, iMedia, Kinder Morgan, Wendy’s and More

Monday’s top analyst upgrades and downgrades included Chipotle Mexican Grill, CRISPR, Hess Midstream, iMedia Brands, Kinder Morgan, Wendy’s and more.